Incoming Teva CEO reviews drug development

Teva developing more than 70 innovative drugs

By GLOBES CORRESPONDENT
April 11, 2012 22:14
1 minute read.
Teva Pharmaceuticals' JEREMY LEVIN

Teva Pharmaceuticals' JEREMY LEVIN 370. (photo credit: REUTERS)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Incoming Teva Pharmaceutical Industries Ltd. President and CEO Jeremy Levin, who will succeed Shlomo Yanai next month, has been reviewing the company’s drug development process. He has not ordered the suspension of drug development, at least for most drugs.

Teva is developing more than 70 innovative drugs, mostly acquired through the acquisition of Cephalon for $6.8 billion last year. Levin, who previously managed strategy for Novartis AG, is reviewing Teva’s drug development system ahead of his taking office next month, so at least until then no decisions are expected over the development of which drugs will be pursued, and which will be terminated.

Be the first to know - Join our Facebook page.


The review process is routine as part of Levin’s taking office. In the past few months, he has been studying Teva with Yanai. Sources say that the cooperation between the two men has been exceptional.

When Teva announced Levin’s appointment at a special press conference in late 2011, Levin implied that Teva would focus on the development of innovative drugs. Development costs of such drugs are high, but the payoff on success can be even higher in terms of profits.

Teva’s multiple sclerosis intravenous treatment drug, Copaxone, is a good example. It is the leading global treatment for the disease, accounted for an estimated one third of the company’s profits. Teva is trying to develop new brand drugs to take its place when its patents expire in 2014-2015.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS